Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb dose-finding study of Bavisant for excessive daytime sleepiness in Parkinson's disease
2017-000877-35Phase 2Completed
- Sponsor
- BenevolentAI
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Bavisant with Placebo (2 arms). Primary endpoint: Change in Epworth Sleepiness Scale at 6 weeks. Started Jun 2017; status: completed.
02
Drugs
bavisant
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-000877-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000877-35.